Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

1b trials with dupilumab (REGN668), an antibody targeting IL-4R, in atopic dermatitis were presented at the 71st Annual Meeting of the American Academy of Dermatology in March 2013.  Data from a Phase 2a trial of dupilumab in allergic asthma will be presented at the American Thoracic Society meeting in May 2013.  Dupilumab is being developed in collaboration with Sanofi.

First Quarter 2013 Financial ResultsTotal Revenues: Total revenues were $440 million in the first quarter of 2013, compared to $232 million in the first quarter of 2012.  Total revenues include collaboration revenues of $114 million in the first quarter of 2013, compared to $97 million in the first quarter of 2012. 

Product Revenues: Net product sales were $319 million in the first quarter of 2013, compared to $128 million in the first quarter of 2012.  EYLEA net product sales were $314 million in the first quarter of 2013, compared to $124 million in the first quarter of 2012.  ARCALYST net product sales were $5 million in the first quarter of 2013, compared to $4 million in the first quarter of 2012.  

Research and Development (R&D) Expenses: GAAP R&D expenses were $180 million in the first quarter of 2013, compared to $139 million in the first quarter of 2012.  The higher R&D expenses in 2013 were principally due to increased R&D headcount and activities, primarily related to the Company's antibody collaboration with Sanofi, and higher non-cash share-based compensation expense.  In the first quarter of 2013, R&D related non-cash share-based compensation expense was $27 million, compared to $11 million in the first quarter of 2012.

Selling, General, and Administrative (SG&A) Expenses: GAAP SG&A expenses were $77 million in the first quarter of 2013, compared to $58 million in the first quarter of 2012.  The increase was primarily due to higher expenses in connection with
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... 21, 2014 The College of New ... college in the Mid-Hudson Region to be designated as ... accepting applications from qualified “high-technology” businesses that align with ... pleased to have been selected for the START-UP NY ... initiative to stimulate economic development in New York by ...
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... 26 Verenium Corporation (Nasdaq: VRNM ), ... enzyme solutions, today announced that it has renewed and ... leading global provider of heat transfer, separation and fluid ... Alfa Laval signed an agreement to jointly market enzymatic ...
... Pa. and LEUSDEN, Netherlands, Oct. 26 Molecular ... designed to increase the speed and accuracy of ... distributor Westburg BV today announced that they have ... MDI,s Detect-Ready MRSA panel in the Benelux region. ...
... 26 iDiverse announced that it has successfully modified ... lethal stresses normally encountered in the bioproduction of fuel ... to generate significantly more ethanol. "We ... and are rapidly developing a 2nd generation with yet ...
Cached Biology Technology:Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 2Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 3Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 4Molecular Detection Inc. Announces MSSA Label Expansion and Benelux Distribution Agreement for Its Detect-Ready™ MRSA Screening Test 2Molecular Detection Inc. Announces MSSA Label Expansion and Benelux Distribution Agreement for Its Detect-Ready™ MRSA Screening Test 3Molecular Detection Inc. Announces MSSA Label Expansion and Benelux Distribution Agreement for Its Detect-Ready™ MRSA Screening Test 4Molecular Detection Inc. Announces MSSA Label Expansion and Benelux Distribution Agreement for Its Detect-Ready™ MRSA Screening Test 5iDiverse Develops Stress Resistant Yeast for Producing Fuel Ethanol 2
(Date:8/21/2014)... study of American singles found that during sex ... orgasm rates. On average, men experience orgasm 85.1 ... making little difference. For women, however, orgasm occurrence ... 62.9 percent of the time during sex with ... with women,s sexual orientation, with lesbian women experiencing ...
(Date:8/21/2014)... linked to dandruff, eczema and other itchy, flaky maladies ... global reachesincluding Hawaiian coral reefs and the extreme environments ... review in the scientific journal PLOS Pathogens ... of the genus Malassezia in light of ... around the world. , University of Hawai,i at Mānoa ...
(Date:8/21/2014)... In a finding that has implications for life in ... in the solar system, LSU Associate Professor of Biological ... National Science Foundation, or NSF, this week published a ... lake that lies 800 meters (2600 feet) beneath the ... microbial ecosystems.", Given that more than 400 subglacial lakes ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4
... Philadelphia, PA, March 1, 2012 Down syndrome ... born children arising as a consequence of a chromosomal ... copies of chromosome 21, instead of the usual two. ... cognitive dysfunction that can range from mild to severe ...
... is the largest sea turtle in the world, growing ... also one of the most threatened. A major new ... zonesin the Pacific Ocean for this critically endangered species. ... practices to help reduce further deaths of this fragile ...
... A*STAR scientists have for the first time, identified that ... stem cell (ESC) self-renewal the ability of ESCs to ... for better understanding of ESC regulation and was published in ... by the team of scientists from the Institute of Medical ...
Cached Biology News:Understanding and treating the cognitive dysfunction of Down syndrome and Alzheimer's disease 2Leatherback turtle migration study identifies Pacific danger zones for endangered species 2A*STAR scientists make groundbreaking discovery on stem cell regulation 2
... The ImageXpress 5000A automated cellular imaging and ... software system designed specifically for rapid acquisition ... throughput cell-based screening. ImageXpress is fast. ... resolution (1280 x 1024 pixels), with two ...
...
... Custom Peptide Services offer a full range ... research needs. Services include: Peptide synthesis, ... Peptide synthesis, purified product (70-95% pure) ... amidation, biotinylation, fluorescein, myristylation, phosphorylation, and rhodamine) ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...
Biology Products: